INO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-27), Inovio Pharmaceuticals's current share price is $10.57. Inovio Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $22.20. Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.48.
The historical rank and industry rank for Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Inovio Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 18.50. The lowest was 0.19. And the median was 3.05.
INO's Cyclically Adjusted PB Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Inovio Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was $5.148. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $22.20 for the trailing ten years ended in Dec. 2023.
The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inovio Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 0.84 | 0.44 | 0.24 | 0.21 | 0.28 |
For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 10.57 | / | 22.2 | |
= | 0.48 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inovio Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Inovio Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:
Adj_Book | = | Book Value per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 5.148 | / | 129.4194 | * | 129.4194 | |
= | 5.148 |
Current CPI (Dec. 2023) = 129.4194.
Inovio Pharmaceuticals Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201403 | 25.733 | 99.695 | 33.406 |
201406 | 24.239 | 100.560 | 31.195 |
201409 | 23.170 | 100.428 | 29.859 |
201412 | 21.974 | 99.070 | 28.706 |
201503 | 20.372 | 99.621 | 26.466 |
201506 | 30.173 | 100.684 | 38.784 |
201509 | 32.109 | 100.392 | 41.393 |
201512 | 29.193 | 99.792 | 37.860 |
201603 | 28.390 | 100.470 | 36.570 |
201606 | 26.454 | 101.688 | 33.668 |
201609 | 23.829 | 101.861 | 30.276 |
201612 | 19.975 | 101.863 | 25.379 |
201703 | 17.020 | 102.862 | 21.414 |
201706 | 19.079 | 103.349 | 23.892 |
201709 | 21.532 | 104.136 | 26.760 |
201712 | 18.911 | 104.011 | 23.531 |
201803 | 14.949 | 105.290 | 18.375 |
201806 | 14.613 | 106.317 | 17.788 |
201809 | 13.161 | 106.507 | 15.992 |
201812 | 10.730 | 105.998 | 13.101 |
201903 | 9.546 | 107.251 | 11.519 |
201906 | 6.526 | 108.070 | 7.815 |
201909 | 4.082 | 108.329 | 4.877 |
201912 | 0.407 | 108.420 | 0.486 |
202003 | 15.159 | 108.902 | 18.015 |
202006 | 14.079 | 108.767 | 16.752 |
202009 | 23.201 | 109.815 | 27.343 |
202012 | 29.615 | 109.897 | 34.876 |
202103 | 33.340 | 111.754 | 38.610 |
202106 | 29.040 | 114.631 | 32.786 |
202109 | 25.874 | 115.734 | 28.933 |
202112 | 22.063 | 117.630 | 24.274 |
202203 | 18.812 | 121.301 | 20.071 |
202206 | 14.432 | 125.017 | 14.940 |
202209 | 12.828 | 125.227 | 13.258 |
202212 | 10.543 | 125.222 | 10.896 |
202303 | 9.099 | 127.348 | 9.247 |
202306 | 7.582 | 128.729 | 7.623 |
202309 | 6.147 | 129.860 | 6.126 |
202312 | 5.148 | 129.419 | 5.148 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Lota S. Zoth | director | 334 CR 692, BUFFALO GAP TX 79508 |
David B. Weiner | director | 717 BEACOM LANE, MERION STATION PA 19066-1603 |
Simon X Benito | director | 967 LAWRENCE AVE, WESTFIELD NJ 07090 |
Michael John Sumner | officer: Chief Medical Officer | 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Laurent Humeau | officer: Chief Scientific Officer | C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Jacqueline Elizabeth Shea | officer: Chief Operating Officer | C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Peter Kies | officer: CFO | |
Roger D Dansey | director | 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Jong Joseph Kim | director, officer: Chief Executive Officer | 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Jay Shepard | director | 15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030 |
Ann Calby Miller | director | C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Wendy L Yarno | director | |
Morton Collins | director | |
George Bickerstaff | director | C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511 |
Niranjan Sardesai | officer: Chief Operating Officer | VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422 |
From GuruFocus
By PRNewswire PRNewswire • 03-01-2023
By PRNewswire PRNewswire • 04-17-2023
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire • 10-10-2023
By PRNewswire PRNewswire • 05-23-2023
By PRNewswire PRNewswire • 05-05-2023
By PRNewswire • 07-26-2023
By PRNewswire • 08-29-2023
By PRNewswire PRNewswire • 05-25-2023
By PRNewswire PRNewswire • 04-28-2023